There’s no need to renegotiate the old agreement insofar as a settlement with Amphastar can be negotiated de novo.
Understood insofar as the Amphostar settlement proposal. But I am referring to another issue that dovetails into the Ampho issue only because both NVS and MNTA would need to agree to any settlement to begin with.
This might be a good time to renegotiate with NVS......not to do a deal with Ampho specifically but to undo the "harm" that the royalty arrangement has done to MNTA's stock.
There is no logical reason, irrespective of number of generics on market, that MNTA should have anything other than a profit sharing arrangement. I understand that at the time, MNTA was negotiating from weakness......but they are no longer weak.
Time to leverage their IP, knowhow, future opportunities amongst "friends".......start with NVS.
Market Data 
Markets 
AI
